USA flag logo/image

An Official Website of the United States Government

Modified Nanoparticles for Lipophilic Toxin Sequestration

Award Information

Agency:
Department of Defense
Branch:
Air Force
Award ID:
Program Year/Program:
2013 / STTR
Agency Tracking Number:
F10B-T24-0250
Solicitation Year:
2010
Solicitation Topic Code:
AF10-BT24
Solicitation Number:
2010.B
Small Business Information
AuraSense, LLC
8045 Lamon Avenue Suite 410 Skokie, IL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: Modified Nanoparticles for Lipophilic Toxin Sequestration
Agency / Branch: DOD / USAF
Contract: FA9550-13-C-0007
Award Amount: $749,646.00
 

Abstract:

ABSTRACT: Mycotoxins are toxic secondary metabolites of molds and fungi, many of which are pathogenic to humans. In general, mycotoxins enter the body through the skin, digestive tract, or through respiration. Exposure to a few milligrams can be lethal. Mycotoxins have a high likelihood of being weaponized, due to their ease of large scale production. One possible way to counteract the effect of mycotoxins is to neutralize them by sequestration in lipophilic membranes, apart from cell membranes. Using cholesterol as a safe and relevant model system for sequestering membrane incorporated lipophilic toxins, AuraSense proposes to use lipid and protein-modified gold nanoparticles to develop constructs for the sequestration of toxic lipophilic molecules. In Phase I, AuraSense demonstrated that the mycotoxin binding nanoparticles synthesized were able to sequester the toxin analogue in buffered saline solutions and in in vitro cell culture assays. In Phase II, AuraSense will extend these experiments in to in vivo systems and examine the ability of the nanoparticles to sequester and excrete these toxins. BENEFIT: The key technological objective in this proposal is to demonstrate that a mycotoxin binding platform is a useful therapy for combating the toxic effects of exposure. AuraSense's mycotoxin binding nanoparticles (MB NP) constructs address a key unmet need: the lack of effective agents for transporting lipophilic toxins, such as mycotoxins, safely out of the body. In response to this unmet need, the Company's objective is a medical countermeasure based upon the MB NP platform and tailored for use against major classes of lipophilic toxins in a field setting. Such a product, if properly configured, could prove essential in responding to a particularly dangerous, and plausible, terrorist or foreign military attack.

Principal Investigator:

Weston Daniel
Research Scientist
(847) 673-1700
wdaniel@aurasense.com

Business Contact:

Percy V. Crocker
VP of Commercial Development
(847) 673-1702
pcrocker@aurasense.com
Small Business Information at Submission:

AuraSense, LLC
8045 Lamon Avenue Suite 410 Skokie, IL -

EIN/Tax ID: 264171829
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Northwestern University
303 E. Superior St.
Robert H. Lurie Building
Chicago, IL 60611
Contact: Shad Thaxton
Contact Phone: (773) 957-9503